CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer

Pharmacogenomics

Volumn 11, Issue 8, 2010, Pages 1105-1113

  Metzger, Ralf ^a   Heukamp, Lukas ^b   Drebber, Uta ^a   Bollschweiler, Elfriede ^a   Zander, Thomas ^a   Hoelscher, Arnulf H ^a   Warnecke Eberz, Ute ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

cDNA microarray; chemosensitivity; differential gene expression; multimodality treatment; prognosis; radiosensitivity; RT PCR

Indexed keywords

CENTROMERE PROTEIN N; CHROMATIN ASSEMBLY FACTOR 1; CISPLATIN; COMPLEMENTARY DNA; CULLIN; CULLIN 2; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 4; LEUKOTRIENE B4 RECEPTOR; MESSENGER RNA; NOTCH RECEPTOR; NUCLEIC ACID BINDING PROTEIN; PROTEIN KINASE LKB1; PROTEIN SH2; PROTEIN SWI; S PHASE KINASE ASSOCIATED PROTEIN; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; DOWN REGULATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR REGRESSION;

CULLIN PROTEINS; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955604297     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.76     Document Type: Article

References (39)

1. Rouvelas I, Zeng W, Lindbld M, Viklund P, Ye W, Lagergren J: Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol. 6, 864-870 (2005).
2. Sherman, CA, Turrisi, AT, Wallace MB, Reed CE: Locally advanced esophageal cancer. Curr. Treat. Options Oncol. 3, 475-485 (2002).
3. Leichman CG, Benedetti JK, Zalupski MM et al.: Assessment of infusional 5-fuorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study. Clin. Colorectal Cancer 5, 119-123 (2004).
4. Kaklamanos I, Walker G, Ferry K, Franceshi D, Livingstone AS: Neoadjuvant treatment for respectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann. Surg. Oncol. 10, 754-761 (2003).
5. Urschel J, Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for respectable esophageal cancer. Am. J. Surg. 185, 538-543 (2003).
6. Fiorica F, Di Bona D, Schepis F et al.: Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53, 925-930 (2004).
7. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian GastroIntestinal Trials Group: Survival benefts from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 8, 226-234 (2007).
8. Schneider PM, Baldus SE, Metzger R et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classifcation. Ann. Surg. 242, 684-692 (2005).
9. Haffty BG, Glazer PM: Molecular markers in clinical radiation oncology. Oncogene 22, 5915-5925 (2003).
10. Lagarde SM, ten Kate FJW, Richel DJ, Offerhaus GJ, van Lanschot JJ: Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann. Surg. Oncol. 14, 977-991 (2006).
11. Metzger R, Leichman CG, Danenberg KD et al.: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fuorouracil chemotherapy. J. Clin. Oncol. 16, 309-316 (1998).
12. Warnecke-Eberz U, Metzger R, Miyazono F et al.: High specifcity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res. 10, 3794-3799 (2004).
13. Miyazono F, Metzger R, Warnecke-Eberz U et al.: Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histophathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br. J. Cancer 16, 666-672 (2004).
14. Freidin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: design issues. J. Natl Cancer Inst. 102, 152-160 (2010).
15. Warnecke-Eberz U, Metzger R, Bollschweiler E et al.: Quantitative low density arrays and analysis by artifcial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 11(1), 55-64 (2010).
16. Baldus SE, Mönig SP, Schröder W et al.: Regression of oesophageal carcinoms after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe 25, 4780-4788 (2004).
17. Bollschweiler E, Metzger R, Drebber U et al.: Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann. Oncol. 20, 231-238 (2009).
18. Walker SJ, Wang Y, Grant KA, Chan F, Hellmann GM: Long versus short oligonucleotide microarrays for the study of gene expression in nonhuman primates. J. Neurosci. Methods 152, 179-189 (2005).
19. Warnecke-Eberz U, Hokita S, Xi H et al.: Overexpression of survivin mRNA is associated with a favourable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol. Rep. 13, 1241-1246 (2005).
20. LeBlanc M, Jacobson J, Crowley J: Partitioning and peeling for constructing prognostic groups. Stat. Methods Med. Res. 11, 247-274 (2002).
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 187-220 (1958).
22. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Chemother. Rep. 50, 163-170 (1966).
23. Maeda Y, Suzuki T, Pan X et al.: CUL2 is required for the activity of hypoxia-inducible factor and vasculogenesis. J. Biol. Chem. 283, 16082-16092 (2008).
24. Hosogi H, Nagayama S, Kawamura J et al.: Molecular insights into Peutz-Jeghers syndrome: two probands with a germline mutation of LKB1. J. Gastroenterol 43, 492-497 (2008).
25. Liang J, Shao SH, Xu ZX et al.: The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9, 218-224 (2007).
26. Macowski L, Hayes DN: Role of LKB1 in lung cancer development. Br. J. Cancer 99, 683-688 (2008).
27. Koivunen JP, Kim J, Lee J et al.: Mutations in the LKB1 tumor suppressor are frequently detected in tumors from Caucasian but not Asian lung cancer patients. Br. J. Cancer 99, 245-252 (2008).
28. Ossipova O, Bardeesy N, DePinho RA, Green JB: LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. Nat. Cell Biol. 5, 889-894 (2003).
29. van Amerongen R, Mikels A, Nusse R: Alternative Wnt signaling is initiated by distinct receptors. Cell Biol. 35, 1-5 (2008).
30. Fumoto S, Shimokuni T, Tanimoto K et al.: Selection of a novel drug response predictor in esophageal cancer: a novel screening method using microarray and identifcation of IFITM1 as a potent marker gene of CDDP response. Int. J. Oncol. 32, 413-423 (2008).
31. Vilmar A, Sorensen JB: Excision repair cross-complementation group1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64, 131-139 (2009).
32. Luthra R, Wu TT, Luthra MG et al.: Gene expression profling of localized esophageal carcinomas: association of pathologic response to preoperative chemoradiation. J. Clin. Oncol. 24, 295-297 (2006).
33. Ashida A, Boku N, Aoyagi K et al.: Expression profling of esophageal squamous cell carcinoma patients treated with defnitive chemoradiotherapy: clinical implications. Int. J. Oncol. 28, 1345-1352 (2006).
34. Duong C, Greenawalt DM, Kowalczyk A et al.: Pretreatment gene expression profles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann. Surg. Oncol. 14, 3602-3609 (2007).
35. Li W, Liu BY, Zhang XQ et al.: Analysis of human gastric cancer by transcriptome and proteome profling. Zhonghua Wei Chang Wai Ke Za Zhi 12, 52-56 (2009).
36. Mönig SP, Schröder W, Baldus SE, Hölscher AH: Preoperative lymph node staging in gastrointestinal cancer-correlation between size and tumour stage. Onkologie 25, 342-344 (2002).
37. Schröder W, Baldus SE, Mönig S, Hölscher AH: Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. World J. Surg. 26, 584-587 (2002).
38. Bollschweiler E, Hölscher AH, Metzger R: Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncol. 6(1), 25-35 (2010).
39. Maher SG, Gillham CM, Duggan SP et al.: Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann. Surg. 250, 729-737 (2009).